 SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 GLOBE NEWSWIRE -- Catalyst Biosciences, Inc. NASDAQ: CBIO presented a poster today at the 62nd Annual American Society of Hematology ASH meeting, held virtually December 5-8, 2020, highlighting its Phase 3 Study, Crimson 1. The study will evaluate Marzeptacog alfa activated or MarzAA, the Companys subcutaneously administered next-generation engineered coagulation Factor VIIa FVIIa. 